ScriptLinkRx Resources
Compounding Guides for Providers
Provider-focused guides on compounded medications — grounded in real ordering data from clinics on ScriptLinkRx, with current regulatory context.
See What Clinics Are Actually Prescribing in 2026
We ranked the 15 most-prescribed compounded medications across the clinics and med spas ordering on ScriptLinkRx — real order volume, not survey guesses. See which formulations are leading demand and what it means for your practice.
GLP-1 & Metabolic
Incretin-based formulations for weight-management and metabolic programs
Compounded Tirzepatide with Pyridoxine (B6): A Provider's Guide
A provider guide to compounded tirzepatide with pyridoxine (B6): essentially-a-copy limits, the 2026 503B bulks proposal, and pharmacy quality questions.
Compounded Semaglutide with Pyridoxine (B6): A Provider's Guide
What clinics should know about compounded semaglutide with pyridoxine (B6): regulatory status after the 2025 shortage resolution, sourcing, and quality.
Compounded Tirzepatide with Cyanocobalamin (B12): What Providers Should Know
Regulatory status, additive justification, and sourcing questions for compounded tirzepatide with B12 — a provider-focused guide, updated July 2026.
Compounded Semaglutide with Cyanocobalamin (B12): What Providers Should Know
Compounded semaglutide with B12: regulatory status after the shortage resolution, additive justification, and pharmacy vetting questions for providers.
Compounded Tirzepatide with L-Carnitine: A Provider's Overview
A provider guide to compounded tirzepatide with L-carnitine: regulatory status, FDA combination scrutiny, and sourcing questions for clinics.
Compounded Tirzepatide with NAD+ and L-Carnitine: Provider Considerations
A regulatory overview of compounded tirzepatide with NAD+ and L-carnitine for providers: the essentially-a-copy framework and two-additive scrutiny.
Retatrutide: Regulatory Status and What Providers Need to Know
Retatrutide is not FDA-approved and cannot legally be compounded as of July 2026. A regulatory fact check for clinics fielding patient questions.
Recovery Peptides
Peptides under active FDA and PCAC review in 2026
BPC-157: Compounding and Regulatory Status for Providers
A regulatory-literate overview of BPC-157's FDA compounding status in 2026, including the April 2026 Category 2 removal and July 2026 PCAC review.
TB-500 (Thymosin Beta-4 Fragment): Provider Overview and Regulatory Status
TB-500, a thymosin beta-4 fragment: a provider overview of its class, compounding forms, limited human evidence, and 2026 FDA regulatory status.
Longevity & Wellness
Compounds ordered by longevity and wellness practices
Compounded NAD+ for Clinics: Forms, Practice Context, and Sourcing
A provider guide to compounded NAD+: what it is, how longevity and wellness clinics use it, its forms, and sterile-compounding questions to ask a pharmacy.
5-Amino-1MQ: What Providers Should Know
5-Amino-1MQ is a research-stage NNMT inhibitor. A regulatory overview for providers weighing its FDA status, evidence gaps, and compounding questions.
Compounded Glutathione: Forms and Provider Considerations
A provider guide to compounded glutathione: forms, sterile-compounding standards, the endotoxin contamination history, and pharmacy sourcing questions.
Hormone & Growth
GH-axis and hormone-adjacent formulations
Sexual Wellness
Sexual-health formulations and their regulatory context
Compounded Oxytocin: What Providers Should Know
A regulatory guide to compounded oxytocin for clinics: nasal spray and troche forms, off-label context, FDA status, and pharmacy sourcing questions.
Bremelanotide (PT-141): Compounded Forms and Provider Considerations
A regulatory-literate overview of compounded PT-141 (bremelanotide) for clinics: mechanism, forms, essentially-a-copy analysis, and sourcing due diligence.
Skin & Aesthetics
Topical and aesthetic formulations for dermatology and med spas